Quest Diagnostics licenses technology underlying SensiTrop HIV co-receptor tropism test from pathway diagnostics -First national diagnostic testing company to license proprietary technology-.Quest Diagnostics Quest Diagnostics Incorporated (NYSE: DGX) is a United States corporation which provides clinical laboratory services . The company also has a business presence in England and Mexico.
Quest Diagnostics is a member of the Fortune 500 and the S&P 500. Incorporated (Madison, NJ), the nation's leading provider of diagnostic testing Diagnostic testing
Testing performed to determine if someone is affected with a particular disease.
Mentioned in: Von Willebrand Disease , information and services, announced that it has entered into a non- exclusive license agreement for the heteroduplex tracking technology underlying Pathway Diagnostics' SensiTrop HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. co-receptor tropism tropism (trōp`ĭzəm), involuntary response of an organism, or part of an organism, involving orientation toward (positive tropism) or away from (negative tropism) one or more external stimuli. test. Tropism refers to the way a virus targets host cells. A molecular-based assay for HIV co-receptor tropism will help physicians personalize therapy for HIV patients. Quest Diagnostics is the first full-service national clinical laboratory in the United States to license the technology. Terms of the agreement were not disclosed.
"Pathway Diagnostics' heteroduplex tracking technology is an important new advance that highlights the growing importance of diagnostics to personalized medicine," said Joyce G. Schwartz, M.D., vice president and chief laboratory officer. "HIV co-receptor tropism tests can help physicians identify which patients, of the estimated 500,000 people in the United States being treated for HIV infection, will benefit from entry inhibitor drugs, the latest development in life-enhancing anti-retroviral therapies."
Pathway Diagnostics' SensiTrop technology is designed to enable physicians to identify the HIV co-receptor tropism status of a patient infected with HIV, the virus that causes AIDS. HIV co-receptor tropism refers to the preference of strains of HIV to bind, activate and infect cells, promoting disease progression, according to the type of co-receptor, specifically CXCR CXCR Chemokine, CXC Motif, Receptor
CXCR Alpha Chemokine Receptor 4 (X4) and CCR 1. CCR - condition code register.
2. CCR - (Database) concurrency control and recovery. 5 (R5), on the surface of the cell. Entry inhibitor anti-retroviral drugs, such as Pfizer's Selzentry therapy, which is the first in its class to be FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. approved, block the CCR5 co-receptor to inhibit disease progression.
Selzentry clinical trials showed that patients infected with CXCR4 or X4/R5 viral mixtures were at an increased risk for treatment failure taking Selzentry, and therefore should not receive the drug. Pathway Diagnostics' technology detects the CXCR4 HIV co-receptor in patient samples that have as little as one percent CXCR4-tropic virus, enabling physicians to identify with a high degree of accuracy those patients with X4-tropic virus who are unlikely to benefit from, and should not receive, treatment with entry inhibitor therapies. The heteroduplex tracking technology, which is molecular based, also can yield test results within seven days of receiving a specimen, compared to up to four weeks to receive results with cellular-based methods. During the first quarter 2008, Quest Diagnostics expects to develop an in-house laboratory validated assay based on the licensed technology. Until then and beginning November 1, 2007, physicians may order SensiTrop through Quest Diagnostics, which will refer the test to Pathway Diagnostics.
"Offering a molecular-based HIV co-receptor tropism assay through Quest Diagnostics will give the greatest number of patients the opportunity to take advantage of Selzentry and future drug therapies in its class," said Walter Narajowski, chief executive officer, Pathway Diagnostics. "Quest Diagnostics' top-tier scientific and medical staff track record of quality, innovation, and service excellence distinguishes it as a front runner in the race to provide diagnostics that will help physicians potentially delay disease progression and the onset of AIDS in their HIV-infected patients."
HIV, or the human immunodeficiency virus human immunodeficiency virus
Human immunodeficiency virus (HIV)
A transmissible retrovirus that causes AIDS in humans. , is a retrovirus retrovirus, type of RNA virus that, unlike other RNA viruses, reproduces by transcribing itself into DNA. An enzyme called reverse transcriptase allows a retrovirus's RNA to act as the template for this RNA-to-DNA transcription. that infects cells of the human immune system immune system
Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , destroying or impairing their function. The most advanced stage of HIV infection is AIDS, or acquired immunodeficiency syndrome acquired immunodeficiency syndrome, see AIDS. . HIV can take up to 15 years to develop into AIDS, a process that antiretroviral drugs Antiretroviral Drugs Definition
Antiretroviral drugs inhibit the reproduction of retroviruses—viruses composed of RNA rather than DNA. The best known of this group is HIV, human immunodeficiency virus, the causative agent of AIDS. can help delay. The World Health Organization estimates that approximately 1.2 million people over the age of 15 in the United States were infected with HIV in 2005, the most recent year for which data is available.
Pathway Diagnostics Corporation focuses on the development, validation and performance of novel, proprietary biomarker assays across multiple disease areas that address unmet medical needs and improve patient care. The company combines assay development expertise with a broad range of advanced technology platforms, a fully licensed CLIA CLIA Clinical Laboratory Improvement Amendments of 1988 Congressional legislation that promulgated quality assurance practices in clinical labs, and required them to measure performance at each step of the testing process from the beginning to the end-point of a laboratory, and a growing portfolio of patent-protected biomarkers for pharmaceutical companies to use in drug development and for commercial reference laboratories and in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment.
In an artificial environment outside a living organism. diagnostic manufacturers to license for use in patient testing. Pathway effectively bridges the gap between biomarker research and biomarker testing, as well as ensures a regulatory-compliant environment for laboratory testing for preclinical and clinical drug development programs.
Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.
Quest Diagnostics Incorporated
Pathway Diagnostics Corporation